| Literature DB >> 31396174 |
Qian Yao1, Linglin Gao1, Teng Xu1, Yun Chen1, Xin Yang1, Mengmeng Han1, Xiaotao He1, Chengheng Li1, Ruigang Zhou1, Yuhui Yang1.
Abstract
Staphylococcus aureus is a zoonotic pathogen that causes various life-threatening diseases. The mechanisms of action of amoxicillin against S. aureus are unclear. Here, we established a rabbit tissue cage infection model to evaluate the relationship between the pharmacokinetic/pharmacodynamic (PK/PD) parameters of amoxicillin and selective enrichment of resistant strains of S. aureus and to elucidate the evolution of its resistance to amoxicillin. S. aureus was injected into the tissue cages at 1010 colony forming units (CFU)/mL. We injected different intramuscular concentrations of amoxicillin at doses of 5, 10, 20, and 30 mg/kg body weight once a day for 5 days and 5, 10, 20, and 30 mg/kg body weight twice a day for 2.5 days. Differences in gene expression between two differentially resistant strains and a sensitive strain were evaluated using Illumina sequencing followed by COG and KEGG analysis. RT-qPCR was carried out to validate the difference in protein translation levels. Our results demonstrated that the emergence of resistant bacteria was dose dependent within a given time interval. In the same dosage group, the appearance of resistant bacteria increased with time. The resistant bacteria showed cumulative growth, and the level of resistance increased over time. The resistant bacteria were completely inhibited when the cumulative percentage of time over a 24-h period that the drug concentration exceeded the mutant prevention concentration (MPC) (%T > MPC) was ≥52%. We also found that mecA and femX in S. aureus played a leading role in the development of resistance to amoxicillin. In conclusion, it provide references for optimizing amoxicillin regimens to treat infections caused by S. aureus.Entities:
Keywords: Staphylococcus aureus; administration regimen; amoxicillin; resistance mechanisms; resistant bacteria; tissue cage infection model
Year: 2019 PMID: 31396174 PMCID: PMC6662548 DOI: 10.3389/fmicb.2019.01638
Source DB: PubMed Journal: Front Microbiol ISSN: 1664-302X Impact factor: 5.640
Primers for RT-qPCR.
| Forward (5′-3′) | 5′-TGACACTATGCAAGGTCGTTTCAC-3′ | |
| Reverse (5′-3′) | 5′-TCAGAACCGTCTAACTCTTGGTGG-3′ | |
| Forward (5′-3′) | 5′-TACTGCTATCCACCCTCAAACA-3′ | |
| Reverse (5′-3′) | 5′-ATTTCACCTTGTCCGTAACCTG-3′ | |
| Forward (5′-3′) | 5′-AGCGTGTGTTAGTGCCTTTAGCGT-3′ | |
| Reverse (5′-3′) | 5′-CCATTGCACTGCATAACTTCCGGC-3′ | |
| Forward (5′-3′) | 5′-TTACAGAGTTAACTGTTACC-3′ | |
| Reverse (5′-3′) | 5′-ATACAAATCCAGCACGCTCT-3′ | |
| Forward (5′-3′) | 5′-TCGTGACGGTGAAGTTCAGG-3′ | |
| Reverse (5′-3′) | 5′-CACGCGTTAAGAAGCCATCG-3′ |
FIGURE 1Concentration-time curves of amoxicillin against Staphylococcus aureus in the tissue-cage model after the first dose, the third dose, and the fifth dose. Panel (A) was twice daily and (B) was once daily dosing; n, Number of animals per group.
Pharmacokinetic parameters of amoxicillin at different concentrations for twice daily administration.
| t1/2ka (h) | 3.999 ± 0.001 | 3.614 ± 0.028 | 3.342 ± 0.081 | 3.547 ± 0.106 |
| t1/2 (h) | 4.265 ± 0.012 | 3.964 ± 0.015 | 4.230 ± 0.011 | 3.863 ± 0.065 |
| Tmax (h) | 5.957 ± 0.140 | 5.459 ± 0.132 | 5.412 ± 0.139 | 5.338 ± 0.044 |
| Cmax (μg/mL) | 0.285 ± 0.094 | 1.247 ± 0.160 | 3.478 ± 0.028 | 4.783 ± 0.127 |
| AUC0–12
| 1.393 ± 0.134 | 5.544 ± 0.028 | 12.419 ± 0.024 | 19.606 ± 0.075 |
Pharmacokinetic parameters of amoxicillin at different concentrations for once daily administration.
| t1/2ka (h) | 3.859 ± 0.012 | 3.465 ± 0.033 | 2.413 ± 0.102 | 2.528 ± 0.013 |
| t1/2 (h) | 4.184 ± 0.008 | 4.407 ± 0.017 | 5.874 ± 0.020 | 4.871 ± 0.002 |
| Tmax (h) | 5.796 ± 0.023 | 5.624 ± 0.075 | 5.256 ± 0.073 | 4.974 ± 0.521 |
| Cmax (μg/mL) | 0.198 ± 0.016 | 0.960 ± 0.021 | 2.832 ± 0.142 | 3.906 ± 0.072 |
| AUC0–24 h (μg⋅h/mL) | 1.916 ± 0.113 | 7.863 ± 0.013 | 18.140 ± 0.090 | 29.421 ± 0.570 |
FIGURE 2Antibacterial curve of different drug concentrations in tissue fluid for twice daily (A) and once daily (B) dosing; n, number of animals per group.
FIGURE 3Time-killing curves of amoxicillin against S. aureus at different doses in the tissue-cage model. Amoxicillin at doses of 5, 10, 20, and 30 mg/kg body weight (bw) twice daily for 2.5 days (A1–A4) and 5, 10, 20, and 30 mg/kg bw once daily for 5 days (B1–B4); n represents the number of animals per group.
FIGURE 4Statistic data of the relationship between resistance mutation and pharmacokinetic/pharmacodynamic parameters of amoxicillin. (A) Represents the effect of dose concentration on %T > MIC99 under different dosing schemes. (B) Represents the effect of dose concentration on %T > MPC under different dosing schemes. Above the dotted line indicates sensitive strain; n, number of animals per group.
FIGURE 5Real-time quantitative PCR results based on experiments performed on control and different resistant genes from S. aureus. Data are presented as fold changes between susceptible strain (white), filtrate from 2MIC (gray), and 8MIC (black) resistant strains (n = 3, asterisk* represents upregulation, 0.01 < p < 0.05 and ∗∗p < 0.01, hatch mark # represents downregulation 0.01 < p < 0.05).